Chaste Tree

Vitex agnus-castus contains clerodadienol diterpenes that bind dopamine D2 receptors in the anterior pituitary with potency comparable to dopamine itself, suppressing prolactin release via dopaminergic activation. Dopamine antagonists (metoclopramide, haloperidol, domperidone) block dopamine D2 receptors for their therapeutic effect. Co-administration with Vitex may pharmacodynamically antagonize these drugs, reducing their efficacy in treating nausea, hyperprolactinemia, or psychosis.

Avoid co-administration of Vitex with dopamine antagonists used therapeutically (metoclopramide for gastroparesis/nausea, domperidone). For antipsychotics, concurrent Vitex use may undermine D2 receptor blockade required for therapeutic effect. Patients on dopamine antagonists should be informed of this interaction and Vitex should generally be discontinued.

Vitex agnus-castus exerts dopaminergic agonism at D2 receptors via clerodadienol diterpenes, suppressing prolactin to a degree comparable to dopamine itself. Combined use with dopamine agonists (cabergoline, bromocriptine for hyperprolactinemia; pramipexole for Parkinson disease) could cause additive or excessive dopaminergic stimulation, resulting in side effects: nausea, vomiting, postural hypotension, hallucinations, and pathological behaviors (compulsive behaviours).

Monitor closely if Vitex is used alongside dopamine agonists. The combination is not recommended for prolactin management as it is not standardized and may cause excessive prolactin suppression. Patients on dopaminergic Parkinson therapy should avoid Vitex. Inform prescribers of Vitex use.

Vitex agnus-castus binds estrogen and progesterone receptors and modulates LH and FSH secretion. The TGA has received case reports of unintended pregnancy in women using Vitex with levonorgestrel-only oral contraceptives. The proposed mechanism involves Vitex-mediated alteration of hormonal milieu and luteal phase dynamics that may interfere with progestogen-only contraceptive efficacy. Estrogen receptor binding by Vitex constituents may also interact with combined OCP mechanisms.

Women relying on oral contraceptives for pregnancy prevention should be counselled about this potential interaction. Alternative contraception methods (condoms) should be considered during Vitex use. Advise reporting any menstrual irregularities. The TGA has issued a safety alert regarding this interaction.

Atypical antipsychotics act partly through D2 receptor antagonism to control psychotic symptoms. Vitex agnus-castus diterpenes are D2 receptor agonists that could competitively antagonize antipsychotic binding at these receptors, potentially reducing therapeutic efficacy. Additionally, antipsychotics raise prolactin levels (via D2 blockade); Vitex could oppose this prolactin elevation, altering the clinical outcome of prolactin monitoring.

Vitex should be avoided in patients requiring antipsychotic medication. Clinicians managing patients who self-administer Vitex alongside antipsychotics should monitor for reduced symptom control. If Vitex cannot be discontinued, review antipsychotic dose adequacy and monitor mental status closely.

Vitex agnus-castus binds estrogen receptors (ERα and ERβ) and modulates progesterone levels. In women using exogenous estrogens (for menopause, contraception, or gender-affirming therapy), Vitex may modify the net hormonal effect by competing for receptor binding or by altering endogenous hormone production via pituitary LH/FSH suppression. The clinical magnitude of this interaction is not well quantified.

Women on HRT or other estrogen therapies should inform their prescriber before adding Vitex. Monitor for unexpected changes in menopausal symptoms, menstrual patterns, or mood. Since Vitex is sometimes combined with HRT for symptomatic relief, this should be done under medical supervision with attention to any estrogenic or anti-estrogenic symptom shifts.

Levodopa is converted to dopamine and acts on D2 receptors in the basal ganglia and pituitary. Vitex exerts dopaminergic agonism at pituitary D2 receptors via clerodadienols. While peripheral D2 effects of Vitex are unlikely to alter levodopa pharmacodynamics in the brain, additive pituitary dopaminergic stimulation could affect prolactin regulation, and at high Vitex doses, there may be theoretical competition or synergy at central dopamine pathways.

Use Vitex with caution in patients with Parkinson disease on levodopa/carbidopa. Inform the neurologist of Vitex use. Monitor for any change in Parkinson disease symptom control or emergence of dopaminergic side effects (nausea, dyskinesia, hallucinations). Vitex use for gynaecological indications is generally better managed with disease-specific alternatives in this patient population.

Vitex agnus-castus contains flavonoids (casticin and others) demonstrated to bind and activate µ-opioid (MOR) and δ-opioid (DOR) receptor subtypes, but not κ-opioid receptors (KOR). Co-administration with opioid agonist analgesics may produce additive opioid receptor activation, contributing to sedation, respiratory depression, or altered analgesia. In patients on opioid maintenance therapy (buprenorphine, methadone), receptor competition may unpredictably affect opioid effect.

Patients using opioid analgesics should inform their prescriber before starting chaste tree. Monitor for altered analgesic response, unexpected sedation, or respiratory depression. Exercise particular caution in patients on methadone maintenance or buprenorphine therapy, where opioid receptor dynamics require careful management. Consider discontinuing chaste tree before initiating opioid therapy.

Chaste tree and SSRIs are both used for premenstrual dysphoric disorder (PMDD). A randomized clinical trial directly compared chaste tree to fluoxetine for PMDD, showing comparable efficacy via partially overlapping dopaminergic and serotonergic pathways. Co-administration may produce additive dopaminergic and serotonergic effects, causing mood changes or CNS adverse effects. There is also a theoretical risk that chaste tree amplifies SSRI-related sexual dysfunction due to prolactin modulation.

If a patient is already on an SSRI for PMDD or depression and initiates chaste tree, monitor for mood changes, excessive sedation, or new adverse effects. Substituting chaste tree for an SSRI should only be done under medical supervision with gradual tapering. Do not use chaste tree concurrently with an SSRI for PMDD without informing the prescribing clinician.

Chaste tree modulates the hypothalamic-pituitary-gonadal axis, reducing prolactin secretion and influencing LH, FSH, estrogen, and progesterone levels via dopamine D2 receptor agonism. Co-administration with fertility medications that stimulate (clomiphene, letrozole, gonadotropins) or suppress (GnRH agonists/antagonists) the same axis creates potential for unpredictable additive or antagonistic effects on ovarian response, ovulation timing, and luteal phase support, potentially compromising ART cycle outcomes.

Avoid self-medicating with chaste tree during controlled ovarian hyperstimulation protocols or ART cycles. Disclose chaste tree use to the fertility specialist at the outset of treatment planning. The herb should be discontinued prior to initiating formal stimulation cycles. Patients using chaste tree for cycle regulation may wish to transition to monitored fertility care before conception attempts.